Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

DISEASE CHARACTERISTICS:

Diagnosis of solid tumor, Hodgkin's lymphoma, or B-cell non-Hodgkin's lymphoma
Eligible for autologous stem cell transplantation
No pleural effusion, pericardial effusion, or ascites
No T-cell lymphoma

PATIENT CHARACTERISTICS:

Age:

Under 57

Performance status:

Karnofsky 80-100%

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Bilirubin no greater than 1.5 mg/dL (unless due to Gilbert's disease)
SGOT or SGPT no greater than 2 times upper limit of normal
Hepatitis B and C negative

Renal:

Creatinine no greater than 2.0 mg/dL OR
Creatinine clearance at least 60 mL/min

Cardiovascular:

LVEF at least 50%
No congestive heart disease
No history of myocardial infarction within the past year
No coronary artery disease
No history of arrhythmia

Pulmonary:

Diffusion capacity (corrected) at least 60%
FEV_1 at least 65% of predicted

Other:

HIV negative
No history of seizures
No mental disorders requiring medication (e.g., haloperidol)
No active connective tissue disease
No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or any carcinoma in situ
No allergy to gentamicin
No hypersensitivity to E. coli-derived preparations
No history of severe allergy to sargramostim (GM-CSF) or filgrastim (G-CSF)
No systemic infection
Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy:

See Disease Characteristics

Chemotherapy:

Not specified

Endocrine therapy:

No concurrent corticosteroid therapy

Radiotherapy:

Not specified

Surgery:

Not specified

Other:

No contrast dye for 3 weeks after completion of interleukin-2 therapy